Introduction to Medical Pharmacology

Antianginal Drugs

Module 7 — Cardioprotective Background Therapy in Stable Coronary Artery Disease

Question 0 of 18

Drug Classification  ·  Questions 1–6

Identify the pharmacological class or categorical label for each drug or receptor. Vocabulary preparation is sufficient to answer every question in this section.

Question 1

Aspirin is classified as which type of enzyme inhibitor?

  • AIrreversible cyclooxygenase-1 inhibitor
  • BP2Y12 receptor blocker
  • CHydroxymethylglutaryl-coenzyme A reductase inhibitor
  • DRenin-angiotensin system inhibitor

Correct Answer

A) Irreversible cyclooxygenase-1 inhibitor

Rationale

Aspirin is classified as an irreversible inhibitor of cyclooxygenase-1.

Question 2

Clopidogrel is classified as which type of receptor blocker?

  • ACyclooxygenase-1 inhibitor
  • BP2Y12 receptor blocker
  • CHydroxymethylglutaryl-coenzyme A reductase inhibitor
  • DAngiotensin receptor blocker

Correct Answer

B) P2Y12 receptor blocker

Rationale

Clopidogrel is classified as a P2Y12 receptor blocker, the receptor through which adenosine diphosphate normally promotes platelet aggregation.

Question 3

Statins are classified as which type of enzyme inhibitor?

  • ACyclooxygenase-1 inhibitor
  • BP2Y12 receptor blocker
  • CHydroxymethylglutaryl-coenzyme A reductase inhibitor
  • DRenin-angiotensin system inhibitor

Correct Answer

C) Hydroxymethylglutaryl-coenzyme A reductase inhibitor

Rationale

Statins are classified as inhibitors of hydroxymethylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol synthesis.

Question 4

Ramipril is classified as which type of cardioprotective agent?

  • AAngiotensin receptor blocker
  • BStatin
  • CAntiplatelet agent
  • DAngiotensin-converting enzyme inhibitor

Correct Answer

D) Angiotensin-converting enzyme inhibitor

Rationale

Ramipril is classified as an angiotensin-converting enzyme inhibitor.

Question 5

Aspirin's inhibition of cyclooxygenase-1 is classified as which type of binding?

  • AIrreversible
  • BReversible competitive
  • CReversible non-competitive
  • DAllosteric

Correct Answer

A) Irreversible

Rationale

Aspirin's inhibition of cyclooxygenase-1 is classified as irreversible.

Question 6

Clopidogrel's blockade of the platelet P2Y12 receptor is classified as which type of binding?

  • AReversible competitive
  • BIrreversible
  • CReversible non-competitive
  • DPartial agonist

Correct Answer

B) Irreversible

Rationale

Clopidogrel's blockade of the platelet P2Y12 receptor is classified as irreversible.

Core Pharmacology  ·  Questions 7–14

Apply your understanding of drug mechanisms, pharmacokinetics, and adverse effects. Each question requires one reasoning step.

Question 7

Why does a single dose of aspirin produce an antiplatelet effect that substantially outlasts the drug itself?

  • AMature platelets lack a nucleus and cannot synthesize new cyclooxygenase-1 to replace the enzyme aspirin has inhibited
  • BAspirin accumulates in platelet membranes and is released slowly over days
  • CAspirin's active metabolite has a much longer half-life than the parent drug
  • DAspirin permanently alters platelet membrane receptor expression

Correct Answer

A) Mature platelets lack a nucleus and cannot synthesize new cyclooxygenase-1 to replace the enzyme aspirin has inhibited

Rationale

Because mature platelets lack a nucleus and cannot synthesize new enzyme, a single aspirin dose disables cyclooxygenase-1 for the entire remaining lifespan of each affected platelet, producing an antiplatelet effect that substantially outlasts the drug itself.

Question 8

Why does combining aspirin and clopidogrel produce more complete platelet inhibition than either drug alone?

  • AClopidogrel increases absorption of aspirin in the gastrointestinal tract
  • BAspirin prolongs the half-life of clopidogrel's active metabolite
  • CThe two drugs act on two separate platelet activation pathways, so combining them blocks aggregation more completely than blocking either pathway alone
  • DClopidogrel reactivates cyclooxygenase-1 that aspirin has inhibited, allowing a synergistic combined effect

Correct Answer

C) The two drugs act on two separate platelet activation pathways, so combining them blocks aggregation more completely than blocking either pathway alone

Rationale

Aspirin and clopidogrel act on two separate activation pathways, the thromboxane A2 pathway and the P2Y12 receptor pathway. Combining them produces a more complete blockade of platelet aggregation than either drug alone, which is the pharmacological rationale for dual antiplatelet therapy after an acute coronary event.

Question 9

By which mechanism do statins lower plasma low-density lipoprotein cholesterol?

  • AThey directly bind and neutralize circulating low-density lipoprotein particles
  • BInhibiting cholesterol synthesis causes liver cells to increase low-density lipoprotein receptor expression, pulling more cholesterol out of the bloodstream
  • CThey increase fecal excretion of bile acids, depleting the cholesterol pool
  • DThey inhibit intestinal absorption of dietary cholesterol

Correct Answer

B) Inhibiting cholesterol synthesis causes liver cells to increase low-density lipoprotein receptor expression, pulling more cholesterol out of the bloodstream

Rationale

Statins competitively inhibit hydroxymethylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol synthesis. With less cholesterol being made internally, liver cells respond by increasing low-density lipoprotein receptors on their surface, pulling more low-density lipoprotein cholesterol out of the bloodstream.

Question 10

Why do current guidelines recommend high-intensity statin dosing as the starting point for nearly all patients with established coronary artery disease, rather than titrating up to a specific cholesterol target?

  • AHigh-intensity dosing eliminates the need for any lifestyle modification
  • BLow-intensity statin dosing produces unacceptable rates of myopathy
  • CHigh-intensity dosing reduces the need for antiplatelet therapy
  • DCardiovascular benefit correlates with the absolute degree of low-density lipoprotein reduction achieved, rather than reaching a specific target value

Correct Answer

D) Cardiovascular benefit correlates with the absolute degree of low-density lipoprotein reduction achieved, rather than reaching a specific target value

Rationale

Because cardiovascular benefit correlates with the absolute degree of low-density lipoprotein reduction, current guidelines recommend high-intensity statin dosing as the starting point for nearly all patients with established coronary artery disease, rather than starting low and titrating up based on a specific target value.

Question 11

Why do angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce harmful cardiac and vascular remodeling in coronary artery disease?

  • AThey reduce renin-angiotensin-aldosterone system activity, lowering chronic angiotensin II exposure
  • BThey directly inhibit collagen deposition in the myocardium
  • CThey increase coronary blood flow through direct vasodilation of the epicardial arteries
  • DThey reduce platelet aggregation in the coronary microvasculature

Correct Answer

A) They reduce renin-angiotensin-aldosterone system activity, lowering chronic angiotensin II exposure

Rationale

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce the activity of the renin-angiotensin-aldosterone system, lowering blood pressure and reducing the harmful cardiac and vascular remodeling that chronic angiotensin II exposure promotes.

Question 12

Why does every patient with stable coronary artery disease deserve a full trial of optimal medical therapy before revascularization is pursued for hard outcomes such as death or myocardial infarction?

  • ARevascularization carries unacceptably high procedural risk in nearly all patients
  • BOptimal medical therapy provides faster symptom relief than revascularization
  • CIn patients with stable coronary artery disease, optimal medical therapy alone produces death and myocardial infarction outcomes comparable to adding percutaneous coronary intervention
  • DPercutaneous coronary intervention has no effect on angina symptoms

Correct Answer

C) In patients with stable coronary artery disease, optimal medical therapy alone produces death and myocardial infarction outcomes comparable to adding percutaneous coronary intervention

Rationale

A foundational finding in modern cardiology is that, in patients with stable coronary artery disease, optimal medical therapy alone produces outcomes for death and myocardial infarction that are comparable to adding percutaneous coronary intervention, which is why every patient deserves a full trial of optimal medical therapy before revascularization is pursued for these hard outcomes.

Question 13

Given that optimal medical therapy alone produces comparable death and myocardial infarction outcomes to adding percutaneous coronary intervention, why does revascularization remain a legitimate treatment option for some patients with stable coronary artery disease?

  • ARevascularization is required to prevent progression of atherosclerotic plaque elsewhere in the coronary tree
  • BRevascularization provides meaningfully better and faster relief of angina symptoms than medical therapy alone
  • CRevascularization eliminates the need for ongoing antiplatelet therapy
  • DRevascularization reduces the dose of statin therapy required

Correct Answer

B) Revascularization provides meaningfully better and faster relief of angina symptoms than medical therapy alone

Rationale

Revascularization does provide meaningfully better and faster relief of angina symptoms than medical therapy alone, so symptom relief and quality of life remain legitimate reasons to pursue revascularization in patients who remain limited despite a full trial of medical therapy.

Question 14

In stable coronary artery disease without a recent acute coronary event, why is clopidogrel mainly used as an alternative to aspirin rather than routinely combined with it?

  • AClopidogrel and aspirin cannot be safely combined under any circumstances
  • BClopidogrel is less effective than aspirin at inhibiting platelet aggregation
  • CClopidogrel requires hepatic activation that is impaired in stable coronary artery disease
  • DThe added benefit of combining the two pathways is specifically tied to the acute post-event setting rather than chronic stable disease

Correct Answer

D) The added benefit of combining the two pathways is specifically tied to the acute post-event setting rather than chronic stable disease

Rationale

Combining aspirin and clopidogrel is the pharmacological rationale for dual antiplatelet therapy after an acute coronary event. In stable coronary artery disease without a recent acute event, clopidogrel is mainly used as an alternative to aspirin in patients who cannot tolerate it.

Clinical Correlations  ·  Questions 15–18

Apply pharmacological knowledge to clinical scenarios. Each vignette presents a patient situation; the question tests mechanism of action or drug selection.

Question 15

A 61-year-old man with stable coronary artery disease has been taking low-dose aspirin once daily for years. Despite this once-daily dosing, his platelets remain continuously inhibited around the clock. Which of the following best explains why a single daily dose maintains continuous antiplatelet protection?

  • AAspirin has an unusually long plasma half-life of approximately twenty-four hours
  • BEach dose irreversibly inhibits cyclooxygenase-1 in circulating platelets for the remainder of their lifespan, even though the drug itself clears quickly
  • CAspirin accumulates in adipose tissue and is released continuously between doses
  • DAspirin induces permanent downregulation of thromboxane A2 receptors

Correct Answer

B) Each dose irreversibly inhibits cyclooxygenase-1 in circulating platelets for the remainder of their lifespan, even though the drug itself clears quickly

Rationale

Because mature platelets lack a nucleus and cannot synthesize new enzyme, each aspirin dose disables cyclooxygenase-1 for the entire remaining lifespan of each affected platelet. Continuous protection results from this irreversible effect being applied to the rolling population of platelets, not from the drug itself persisting in plasma.

Question 16

A 66-year-old woman with stable coronary artery disease and diabetes has a normal blood pressure of 118/74 mmHg. Her physician starts an angiotensin-converting enzyme inhibitor as part of her cardioprotective regimen. She asks why she needs a blood-pressure-lowering medication when her blood pressure is already normal. Which of the following best explains the rationale for this addition?

  • AThe medication will be discontinued once her diabetes is well controlled
  • BAngiotensin-converting enzyme inhibitors are required before statin therapy can be safely started
  • CHer normal blood pressure reading will be artificially lowered further to maximize cardioprotection
  • DThese agents reduce harmful cardiac and vascular remodeling independent of blood pressure lowering, a benefit that is particularly valuable in patients with diabetes

Correct Answer

D) These agents reduce harmful cardiac and vascular remodeling independent of blood pressure lowering, a benefit that is particularly valuable in patients with diabetes

Rationale

Angiotensin-converting enzyme inhibitors reduce renin-angiotensin-aldosterone system activity and the harmful cardiac and vascular remodeling that chronic angiotensin II exposure promotes. These agents are particularly valuable in patients with diabetes, reduced ejection fraction, or chronic kidney disease, conditions in which this activity is especially harmful, regardless of baseline blood pressure.

Question 17

A 54-year-old man with stable coronary artery disease has a low-density lipoprotein cholesterol level only mildly above normal. His physician starts a high-intensity statin rather than a low-intensity dose. He asks why he needs such an aggressive dose when his cholesterol is barely elevated. Which of the following best explains the rationale for high-intensity dosing regardless of his baseline level?

  • ACardiovascular benefit correlates with the absolute degree of low-density lipoprotein reduction achieved, not with reaching a specific target value
  • BLow-intensity statin dosing is contraindicated in patients with coronary artery disease
  • CHigh-intensity dosing is required to prevent rebound elevation of cholesterol if the statin is later stopped
  • DHigh-intensity dosing reduces the dose of aspirin needed for cardioprotection

Correct Answer

A) Cardiovascular benefit correlates with the absolute degree of low-density lipoprotein reduction achieved, not with reaching a specific target value

Rationale

Because cardiovascular benefit correlates with the absolute degree of low-density lipoprotein reduction achieved, current guidelines recommend high-intensity statin dosing as the starting point for nearly all patients with established coronary artery disease, rather than starting low and titrating to a specific target value based on baseline cholesterol.

Question 18

A 69-year-old man with stable coronary artery disease has completed a full trial of optimal medical therapy, including antiplatelet therapy, a statin, an angiotensin-converting enzyme inhibitor, and antianginal drugs. He continues to have significant angina that limits his daily activities. His physician refers him for percutaneous coronary intervention. Which of the following best explains why this referral is appropriate, even though optimal medical therapy alone produces comparable mortality outcomes?

  • APercutaneous coronary intervention will eliminate his need for ongoing cardioprotective medications
  • BHis continued symptoms indicate that his optimal medical therapy has failed to provide any cardioprotective benefit
  • CRevascularization provides meaningfully better and faster relief of angina symptoms than medical therapy alone, making symptom relief a legitimate indication on its own
  • DPercutaneous coronary intervention is now required because medical therapy has been tried for the maximum allowable duration

Correct Answer

C) Revascularization provides meaningfully better and faster relief of angina symptoms than medical therapy alone, making symptom relief a legitimate indication on its own

Rationale

While optimal medical therapy alone produces comparable death and myocardial infarction outcomes to adding percutaneous coronary intervention, revascularization does provide meaningfully better and faster relief of angina symptoms. Symptom relief and quality of life remain legitimate reasons to pursue revascularization in patients who remain limited despite a full trial of medical therapy.